Pharmacokinetics and Pharmacodynamics of the ETA-Selective Endothelin Receptor Antagonist SPP301 in Healthy Human Subjects

Journal of Clinical Pharmacology

Volumn 44, Issue 1, 2004, Pages 59-66

  Dieterle, Walter ^a   Mann, Jessica ^b,d   Kutz, Klaus ^c  

^a Drug Disposition Consultants ^*  (Germany)

^b Speedel Pharma AG   (Switzerland)

^c AccelPharm   (Switzerland)

^d Speedel Pharma AG   (Switzerland)

Author keywords

Endothelin 1; ETA selective endothelin receptor antagonist; Pharmacodynamics; Pharmacokinetics; SPP301; Tolerability

Indexed keywords

5 HYDROXYMETHYLPYRIDINE 2 SULFONIC ACID [6 METHOXY 5 (2 METHOXYPHENOXY) 2 (PYRIDIN 4 YL)PYRIMIDIN 4 YL]AMIDE; 5 METHYLPYRIDINE 2 SULFONIC ACID [6 METHOXY 5 (2 METHOXYPHENOXY) 2 (PYRIDIN 4 YL)PYRIMIDIN 4 YL]AMIDE; DRUG METABOLITE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; RO 68 5925; SPP 301; UNCLASSIFIED DRUG; ENDOTHELIN RECEPTOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SPP301;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; OTALGIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; VOMITING; BIOAVAILABILITY; DIET RESTRICTION; DOSE RESPONSE; DRUG ANTAGONISM; HALF LIFE TIME; HEART RATE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FASTING; HALF-LIFE; HEART RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN;

EID: 0347625574     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003261047     Document Type: Article

References (14)

1. Rubanyi GM, Polokoff MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
2. Yanagasiwa M, Kurihara H, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-415.
3. Noll G, Wenzel RR, Luescher TF: Endothelin and endothelin antagonists: potential role in cardiovascular and renal diseases. Mol Cell Biochem 1996;157:259-267.
4. Gray GA, Webb DJ: The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996;72:109-148.
5. Opgenorth TJ: Endothelin receptor antagonism. Adv Pharmacol (NY) 1995;33:1-65.
6. A receptor blockade prevents left ventricular remodelling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998;39:600-608.
7. Roux S, Qui C, Sprecher U, Osterwalder R, Clozel JP: Protective effects of endothelin receptor antagonists in dogs with aortic cross-clamping. J Cardiovasc Pharmacol 1999;34:199-205.
8. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
9. Collados MT, Velazquez B, Borbolla JR, Sandoval J, Masso F, Montano LF, et al: Endothelin-1 and functional tissue factor: a possible relationship with severity in primary pulmonary hypertension. Heart Vessels 2003;18:12-17.
10. Bakr AM, Abdalla AF, El-Marsafawy H, Abu-Hashem I, El-Regal M, Amer T, et al: Plasma endothelin-1 concentrations in children with cirrhosis and their relationship to renal function and severity of portal hypertension. J Pediatr Gastroenterol Nutr 2002;35:149-153.
11. Hurlimann D, Enseleit F, Noll G, Luscher TF, Ruschitzka F: Endothelin antagonists and heart failure. Curr Hypertens Rep 2002;4:85-92.
12. Verhaar MC, Grahn AY, van Weerdt AWM, Honing MLH, Morrison PJ, Yang YP, et al: Pharmacokinetic and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. J Clin Pharmacol 2000;49:562-573.
13. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-1465.
14. Loffler BM, Breu V, Clozel M: Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993;333:108-110.